Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2019 | Triplebodies for AML: origin, rationale & development

Georg Fey • 15 Mar 2019
ISAL 2019
Acute Myeloid Leukemia Leukemia Antibodies SPM-2

Georg Fey, PhD, of the University of Erlangen Nuremberg, Erlangen and Nuremberg, Germany, discusses the origin and rationale behind triplebodies, as well as giving an overview of triplebody agents in development. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

More from Georg Fey

2:03
The benefits of dual-targeting triplebodies
Georg Fey • 15 Mar 2019
4:24
Triplebody development process
Georg Fey • 15 Mar 2019

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals